Fladrafinil

Fladrafinil (CRL-40,941), also designated fluorafinil and bisfluoroadrafinil, is a synthetic diphenylmethylsulfinyl hydroxamic acid eugeroic compound first synthesized at Laboratoire L. Lafon in Paris in the late 1970s to early 1980s as part of the benzhydryl sulfinyl series that also produced adrafinil (CRL-40,028) and modafinil (CRL-40,476). The compound is the bis(4-fluoro) ring-substituted derivative of adrafinil and functions as a prodrug that undergoes hepatic amide hydrolysis to yield flmodafinil (CRL-40,940, bisfluoromodafinil), a selective atypical dopamine reuptake inhibitor with a reported dopamine transporter (DAT) Ki of approximately 4,090 nM and 83 percent DAT blockade in vitro [1, 2]. Fladrafinil was disclosed in a 1984 United States patent (US 4,489,095) assigned to Lafon, in which preclinical animal data demonstrated wakefulness promotion and, distinctively, anti-aggressive behavioral effects in rodent aggression paradigms at intraperitoneal doses of 16 to 1,024 mg/kg, a property not shared by the parent compound adrafinil [3]. The anti-aggressive activity, reported at potencies three to four times greater than adrafinil on a weight basis, represented the principal pharmacological distinction identified during the original Lafon screening campaign and suggested a differentiated central nervous system profile relative to the non-fluorinated congeners. Despite these early findings, fladrafinil was never advanced to formal clinical development. No peer-reviewed human pharmacokinetic, efficacy, or safety studies have been published. The compound was not registered in any jurisdiction and was not assigned an International Nonproprietary Name. The pharmacological characterization of fladrafinil therefore rests entirely on the Lafon patent disclosures, on inference from the well-characterized pharmacology of its active metabolite flmodafinil and of the closely related modafinil and adrafinil, and on recent analytical chemistry investigations conducted under the auspices of the World Anti-Doping Agency (WADA) to establish urinary and blood detection markers for anti-doping surveillance [4, 5]. Flmodafinil itself has been characterized as a selective DAT inhibitor that blocks the dopamine transporter at 83 percent occupancy without inducing cytochrome P450 3A4 or 3A5, that maintains wakefulness over a longer timeframe than modafinil in animal models with reduced perturbation of sleep architecture, and that elevates nucleus accumbens dopamine concentrations by approximately 150 to 200 percent at peak doses [1, 2]. The active metabolite has been in preclinical development for chronic fatigue syndrome, though clinical programs for narcolepsy, attention deficit hyperactivity disorder, and Alzheimer’s disease have been discontinued as of early 2024. Fladrafinil entered public awareness principally through the nootropic and dietary supplement markets beginning approximately 2015, where it is sold as a research-grade powder or capsule preparation at purities typically stated as 98 percent or greater. The compound is classified under the WADA Prohibited List as a class S6 non-specified stimulant (prohibited in-competition) and has been the subject of analytical investigations by Krug, Thevis, and colleagues at the German Sport University Cologne into its metabolism, elimination kinetics, and detection windows in urine and dried blood spots [4, 5]. This monograph reviews the chemistry, structural relationships, known and inferred pharmacology, pharmacokinetics, the absence of clinical evidence, sourcing and quality considerations, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five eugeroic and wakefulness-promoting compounds against fladrafinil on five competency standards.